Page 21 - தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: Preliminary data from the expansion cohort are expected during first half 2021 MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the successful dosing of the first patient in the expansion cohort of the Phase 1 alloSHRINK trial for CYAD-101, the Company s allogeneic T cell receptor (TCR) inhibitory molecule (TIM)-based, non-gene edited CAR T candidate for the treatment of refractory metastatic colorectal cancer (mCRC). CAR T therapies historically had little success in treating solid tumors, including advanced metastatic colorectal cancer, said Dr. Eric Van Cutsem, Professor of Internal Medicine at University of Leuven. Based on the encouraging response rate we ve observed from the dose escalation segment of the alloSHRINK trial, we believe that thi

Mont saint guibertWaals gewestNew yorkUnited statesWalloon regionRegion flamandeAnne flamentSara zelkovicEric van cutsemExchange commissionCommunications investor relationsLifesci advisorsClinical development at celyad oncologyInternal medicineClinical developmentCelyad oncology